Discovering and developing transformational precision therapies
Extending the definition of what constitutes human biology
We go beyond human biology when searching for drug targets and therapies
About Company
Proprietary platform
We've built a suite of proprietary tools and capabilities into our platform. These tools have allowed for increased efficiencies, mass data integration, machine learning & identification at the strain level.
Each of our the tools is proprietary to Second Genome. How these tools work together to discover therapeutics and biomarkers are also proprietary and unique to the Second Genome platform.
Learn more
Advancing pipeline
SG-5-00455
- Indication: Inflammatory bowel disorders
-
Peptide:
SG-2-0776 -
Target:
PAI-1 / PAI-2 - IP filed
SG-3-06686
- Indication: solid tumors
-
Peptide:
SG-3-06686
-
Target:
CXCR3
- IP filed
Other
8 additional in early discovery programs
We have two advanced programs in IND-enabling studies. An additional 8 programs are in early discovery.
Latest News
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator
Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
Second Genome platform discovered diverse and novel proteins for Bayer for potential development of next-generation insect-control products
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
SG-5-00455, the Company’s development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2